Which generation of targeted drugs does Mobosetinib/Mobosetinib belong to?

Mobocertinib is an innovative oral small molecule tyrosine kinase inhibitor (TKI) mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The drug is classified as a third-generation EGFR-TKI that specifically targets EGFR exon 20 insertion mutations, a rare and difficult-to-treat type of mutation in patients with non-small cell lung cancer.

1. Mobosetinib is a third-generation EGFR-TKI The reason why EGFR-TKI

Currently, EGFR mutation-targeted treatment has experienced the development of three generations of drugs:

1. First generationEGFR-TKI (such as gefitinib, erlotinib) mainly targets classic EGFR mutations (exon 19 deletion and L858R point mutation), but drug resistance appears quickly, especially the emergence of T790M drug resistance mutation.

2. Second generationEGFR-TKI (such as afatinib, dacomitinib) not only inhibits EGFR mutations, but also targets HER2 mutations, but has greater side effects and has limited effect on overcoming resistance to T790M mutations.

3. Third generationEGFR-TKIs (such as osimertinib, mobosetinib) are specifically designed to overcome T790M resistance mutations or rare EGFR exon 20 insertion mutations, and have higher selectivity, reducing inhibition of wild-type EGFR, thereby reducing side effects.

Mobosetinib is different from osimertinib in that it is the first third-generation EGFR-TKI that specifically targetsEGFR exon 20 insertion mutations. This mutated form is extremely resistant to traditional EGFR-TKI treatment, so the advent of moboxetinib provides a new treatment option for this group of patients.

2. The mechanism of action of mobosetinib

The main mechanism of action of mobosetinib is to irreversibly bind to the EGFR tyrosine kinase domain, especially for tumor cells with EGFR exon 20 insertion mutations, which can effectively block their signaling pathways and inhibit tumor growth. At the same time, due to its high selectivity, mobosetinib is less likely to affect wild-type EGFR, thus reducing adverse reactions such as rash and diarrhea caused by inhibition of wild-type EGFR.

3. Advantages of mobosetinib compared with otherEGFR-TKIs

1. Specificity forEGFR exon 20 insertion mutations: Currently mostEGFR-TKIs (such as first- and second-generation drugs) have poor efficacy against EGFR exon 20 insertion mutations. Mobosertinib is the first oral drug specifically targeting this mutation. Compared with chemotherapy or immunotherapy, it provides better therapeutic effect and tolerability.

2. Oral administration makes treatment more convenient: Traditional treatment methods may involve intravenous injection or combination therapy, while mobosetinib is an oral drug that patients can take at home, improving the convenience and compliance of treatment.

3. Better objective response rate (ORR): Clinical trials show that mobosetinib has a better objective response rate (ORR) in patients with EGFR exon 20 insertion mutations who have failed previous treatments. Research data shows that the drug can enable some patients to achieve longer progression-free survival (PFS) in second-line and above treatments.

4. Good safety and tolerability: Due to the high selectivity of mobosetinib, patients’ side effects are relatively controllable when using the drug. Although common side effects such as diarrhea, oral ulcers, and rashes may still occur, its tolerability is better than traditional chemotherapy or non-specific targeted drugs.

Although moboxetinib brings new treatment hope, it still has certain limitations: allEGFR-TKI drugs will eventually face the problem of drug resistance. The resistance mechanism of moboxetinib is still under study, and combination therapy or a new generation of drugs may be needed to overcome it in the future.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib